1 November 2024 - The November 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are many new/revised listings of note this month:

• Adalimumab (Amgevita) - restriction change
• Aripiprazole monohydrate (Abilify Maintena) - restriction change
• Bendamustine hydrochloride (Bendamustine Sandoz) - new indications
• Cetuximab (Erbitux) - new indications
• Etanercept (Enbrel) - restriction change
• Ferric carboxymaltose (Ferinject) - new indication
• Fosfomycin trometamol (UroFos) - new medicine
• Infliximab (Remicade) - restriction change
• Methylnaltrexone bromide (Relistor) - 
• Nivolumab (Opdivo) - new indication
• Pemetrexed disodium heptahydrate (Pemetrexed-AFT) - new indications (unrestricted listing)
• Secukinumab (Cosentyx) - restriction change

Read New Zealand Pharmaceutical Schedule update